Research study for adults with Stage II or III Rectal Cancer.


A Phase II/III trial of Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision


Hedrick Traci,

The purpose of the study is to see if radiation can be avoided for a select group of rectal cancer patients who have a good response to 6 treatments with a chemotherapy combination regimen known as FOLFOX. The study does not use new drugs or procedures, but instead arranges well-established treatment strategies in a different way and the combination is considered investigational. Participant’s insurance company will be billed for medication, tests and procedures. For more information please contact: • Amy Harrigan • 434-982-6532 • • IRB-HSR # 16375 Principal Investigator: Traci L. Hedrick, MD UVa Health System, Department of Surgery, Division of Colorectal Surgery

General Surgery

Rectal Cancer

Cancer (Oncology)


No Compensation

Amy Harrigan